Olanzapine for young PEople with aNorexia nervosa: An open-label feasibility study to test recruitment, treatment acceptance, adherence, safety, outcome measures and patients' experience to prepare for a randomised placebo-controlled trial (OPEN) [ 1/1/2021 - 12/31/2022 ]

Research Grant

Brief description Olanzapine seems to be a helpful and safe medication in anorexia nervosa (AN), but it is not approved for AN. We will perform a preliminary study with 70 patients with AN (15 in Australia and 50 in the UK, age: 12-24 years) who can safely take olanzapine and have not gained sufficient weight or experienced improvement in their AN symptoms under specialist care. We will the acceptability and feasibility of olanzapine in AN. Patients will be examined after 8 and 16 weeks, 6 months and 12 months.

Funding Amount $190,799

Funding Scheme International Collaborations

Chief Investigator A/Pr Sloane Madden

Notes NHMRC-NIHR Collaborative Research Grants - 2019 Round 3